News Feature | November 20, 2026

Merck Ends Nemtabrutinib Development, Closing Three Phase 3 BELLWAVE Trials

Source: Clinical Supply Leader

By Elizabeth Urbanek, Executive Editor

clinical research, health teamwork, nurse for healthcare, cancer innovation, virus study-GettyImages-1587078646

Merck has discontinued development of nemtabrutinib, an investigational treatment for chronic lymphocytic leukemia (CLL) and other blood cancers, ending three Phase 3 trials. The decision affects investigators, sites, and patients across the company's BELLWAVE clinical program.

Announced Nov. 17, the decision followed a review of the Phase 3 BELLWAVE-011 trial by an external data monitoring committee, which suggested the benefits may not outweigh the risks in that study. Merck said it confirmed this after reviewing the data in its totality and then decided to discontinue the broader program, including the BELLWAVE-008 and BELLWAVE-010 Phase 3 studies.

Nemtabrutinib (MK-1026) is an oral, noncovalent Bruton's tyrosine kinase (BTK) inhibitor. Merck has been studying it in CLL, small lymphocytic lymphoma (SLL), and other hematologic malignancies. BELLWAVE-011 (NCT06136559), which Merck launched in January 2024, was designed to compare nemtabrutinib with investigator's choice of ibrutinib or acalabrutinib in patients with previously untreated CLL or SLL.

Merck said it is informing investigators in the affected trials and advises patients to speak with their study team and physician about next steps and treatment options. Analyses of the data are ongoing, and the company said it will share results with the scientific community.

The announcement does not describe the safety or efficacy findings behind the decision, give a timeline for closing the trials, or say whether current participants will have continued access to nemtabrutinib. It also names other nemtabrutinib studies without stating whether they are affected.

What This Means For Clinical Supply

When a sponsor ends a single study, close-out follows a plan. Ending a whole program means running that plan across several global Phase 3 trials at once, at every depot and site holding investigational medicinal product (IMP).

Because the decision rests on a benefit-risk finding, dosing may stop faster than it would in a planned close-out. Sites will need clear instructions on whether to quarantine stock, how to return it, and how to document what was dispensed. That puts the interactive response technology (IRT) system at the center: Dispensing has to be locked, and inventory records have to match what sites actually hold so reconciliation can close.

Behind the sites sits a larger inventory question. Depot stock, labeled and unlabeled finished goods, bulk drug product, and any planned packaging or manufacturing work would all need decisions, along with country-specific rules for return and destruction.

Comparator stock adds another layer. BELLWAVE-011 used ibrutinib or acalabrutinib as comparators. Commercially sourced comparator that has not been dispensed could be redeployed to other studies, but only if its shelf life, labeling, and sourcing documentation fit the receiving study. Otherwise, it becomes destruction volume and a sunk cost.

The tradeoff is speed against accountability. Pulling IMP back quickly limits the chance of further dosing, but a rushed recall can leave gaps in reconciliation that are harder to close later. Clinical operations, the IRT provider, depots, QA, regulatory affairs, and local affiliates would need to work from one sequence, including any required notifications to regulators and ethics committees.

Participants add one more dependency. As patients move to other treatments, sites may ask about supply for anyone who appears to be benefiting. Merck's announcement does not address continued access, and sponsors in a similar position would need that answer before they can plan final inventory.

For sponsors, the operational question is whether close-out plans written for one study at a time can handle a program-wide stop.

The Supply Question

When a whole program stops at once, do you pull IMP back fast or slow down to get reconciliation right?

Related Clinical Supply Leader Editorials:

About The Editor:

Elizabeth Urbanek is the Executive Editor for Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights and regulatory strategy to the field.

Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.

Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.